Vista Capital Management Sues Illumina for More than $10M Over Rejection of Roche | GenomeWeb

NEW YORK (GenomeWeb News) – A substantial investor in Illumina's stock is suing the company alleging breach of fiduciary duty in connection with Roche's efforts to buy the San Diego-based company and its efforts to fend off that approach.

In a lawsuit filed with the US District Court, Southern District of New York this week, the plaintiffs, Vista Capital Management, seeks damages of more than $10 million.

Based in Geneva, Vista is a privately held financial services firm that owned more than 300,000 shares of Illumina stock during the periods covered by its lawsuit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

Genomics may help the Cavendish banana from succumbing to fungal infections, a trio of researchers writes at the Conversation.